Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society
Raffaele Napoli, Angelo Avogaro, Gloria Formoso, Salvatore Piro, Francesco Purrello, Giovanni Targher, Agostino Consoli
Topics & Concepts
MedicineHypoglycemiaDyslipidemiaDiseaseDiabetes mellitusFatty liverType 2 Diabetes MellitusType 2 diabetesRisk factorIntensive care medicineAdverse effectInternal medicineBioinformaticsEndocrinologyBiologyDiabetes Treatment and ManagementDiabetes Management and ResearchMetabolism, Diabetes, and Cancer